Why A2 Milk, Orthocell, QBE, and Ramelius shares are pushing higher today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.35% to 7,997.6 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:
A2 Milk Company Ltd (ASX: A2M)
The A2 Milk share price is up 2.5% to $8.09. This may have been driven by a broker note out of Citi this morning. According to the note, the broker has reaffirmed its buy rating and $8.20 price target on the infant formula company's shares. The broker highlights that one of A2 Milk's peers in the China market has released a positive update. It believes the update bodes well for the company and particularly the prospects of its new Genesis product range.
Orthocell Ltd (ASX: OCC)
The Orthocell share price is up 4% to $1.54. Investors have been buying this regenerative medicine company's shares this week after it announced the first sales of Striate+ in Germany, Austria and Switzerland. Orthocell's Striate+ is the company's dental guided bone and tissue regeneration product. Management estimates that the global market opportunity for Striate+ is approximately >US$730 million. It notes that the EU and UK markets contribute approximately US$180 million to this. Orthocell is targeting a 20% share of the global market.
QBE Insurance Group Ltd (ASX: QBE)
The QBE share price is up 2.5% to $22.65. This morning, Morgan Stanley retained its overweight rating on this insurance giant's shares with an improved price target of $25.05. The broker is feeling positive about the company's outlook and the insurance industry as a whole. Morgan Stanley also highlights that QBE stands to benefit from increasing demand for cyber insurance with its QCyberProtect offering. The broker's price target implies potential upside of almost 11% for investors over the next 12 months.
Ramelius Resources Ltd (ASX: RMS)
The Ramelius Resources share price is up 6.5% to $2.46. Investors have been buying Ramelius and other ASX gold stocks on Friday following a strong rise in the gold price overnight. The precious metal hit a new record high overnight after US tariffs sparked trade tensions. The spot gold price is currently fetching US$3,082.80, which is up 0.8%. The S&P/ASX All Ordinaries Gold index is up by a sizeable 3.4% at the time of writing.
The post Why A2 Milk, Orthocell, QBE, and Ramelius shares are pushing higher today appeared first on The Motley Fool Australia.
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk and Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025